News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Peplin Inc. Initiates its Final Phase 3 Clinical Trial for PEP005 Gel in AK


7/23/2009 9:03:10 AM

EMERYVILLE, Calif. & BRISBANE, Queensland--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced the initiation of its second non-head Phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to non-head locations, which include the trunk and extremities.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES